vs

Side-by-side financial comparison of Amarin Corp plc (AMRN) and Chatham Lodging Trust (CLDT). Click either name above to swap in a different company.

Chatham Lodging Trust is the larger business by last-quarter revenue ($67.7M vs $45.1M, roughly 1.5× Amarin Corp plc). Chatham Lodging Trust runs the higher net margin — 6.8% vs -23.3%, a 30.1% gap on every dollar of revenue. On growth, Amarin Corp plc posted the faster year-over-year revenue change (7.0% vs -9.8%). Over the past eight quarters, Chatham Lodging Trust's revenue compounded faster (-0.5% CAGR vs -18.3%).

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

Chatham Lodging Trust is a publicly traded real estate investment trust that invests in, owns, and operates upscale extended-stay and select-service premium hotel properties primarily across high-demand urban and suburban markets in the United States. Its portfolio targets assets with strong occupancy rates and steady cash flow from business and leisure traveler segments.

AMRN vs CLDT — Head-to-Head

Bigger by revenue
CLDT
CLDT
1.5× larger
CLDT
$67.7M
$45.1M
AMRN
Growing faster (revenue YoY)
AMRN
AMRN
+16.8% gap
AMRN
7.0%
-9.8%
CLDT
Higher net margin
CLDT
CLDT
30.1% more per $
CLDT
6.8%
-23.3%
AMRN
Faster 2-yr revenue CAGR
CLDT
CLDT
Annualised
CLDT
-0.5%
-18.3%
AMRN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMRN
AMRN
CLDT
CLDT
Revenue
$45.1M
$67.7M
Net Profit
$-10.5M
$4.6M
Gross Margin
Operating Margin
35.5%
15.9%
Net Margin
-23.3%
6.8%
Revenue YoY
7.0%
-9.8%
Net Profit YoY
33.0%
369.9%
EPS (diluted)
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRN
AMRN
CLDT
CLDT
Q1 26
$45.1M
Q4 25
$49.2M
$67.7M
Q3 25
$49.7M
$78.4M
Q2 25
$72.7M
$80.3M
Q1 25
$42.0M
$68.6M
Q4 24
$62.3M
$75.1M
Q3 24
$42.3M
$87.2M
Q2 24
$67.5M
$86.5M
Net Profit
AMRN
AMRN
CLDT
CLDT
Q1 26
$-10.5M
Q4 25
$-1.2M
$4.6M
Q3 25
$-7.7M
$3.5M
Q2 25
$-14.1M
$5.4M
Q1 25
$-15.7M
$1.5M
Q4 24
$-48.6M
$-1.7M
Q3 24
$-25.1M
$4.3M
Q2 24
$1.5M
$6.8M
Gross Margin
AMRN
AMRN
CLDT
CLDT
Q1 26
Q4 25
47.1%
Q3 25
44.7%
Q2 25
69.2%
Q1 25
59.8%
Q4 24
-15.4%
40.7%
Q3 24
38.5%
44.7%
Q2 24
63.4%
46.1%
Operating Margin
AMRN
AMRN
CLDT
CLDT
Q1 26
35.5%
Q4 25
-12.9%
15.9%
Q3 25
-22.4%
12.7%
Q2 25
-22.0%
14.8%
Q1 25
-39.9%
12.1%
Q4 24
-84.3%
7.5%
Q3 24
-59.5%
14.3%
Q2 24
-0.8%
16.3%
Net Margin
AMRN
AMRN
CLDT
CLDT
Q1 26
-23.3%
Q4 25
-2.5%
6.8%
Q3 25
-15.6%
4.5%
Q2 25
-19.4%
6.7%
Q1 25
-37.4%
2.2%
Q4 24
-78.0%
-2.3%
Q3 24
-59.4%
4.9%
Q2 24
2.3%
7.9%
EPS (diluted)
AMRN
AMRN
CLDT
CLDT
Q1 26
Q4 25
$0.00
$0.05
Q3 25
$-0.02
$0.03
Q2 25
$-0.03
$0.07
Q1 25
$-0.04
$-0.01
Q4 24
$-0.12
$-0.08
Q3 24
$-0.06
$0.05
Q2 24
$0.00
$0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRN
AMRN
CLDT
CLDT
Cash + ST InvestmentsLiquidity on hand
$307.8M
$24.4M
Total DebtLower is stronger
$338.9M
Stockholders' EquityBook value
$740.8M
Total Assets
$645.8M
$1.2B
Debt / EquityLower = less leverage
0.46×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRN
AMRN
CLDT
CLDT
Q1 26
$307.8M
Q4 25
$302.6M
$24.4M
Q3 25
$286.6M
$13.2M
Q2 25
$298.7M
$17.2M
Q1 25
$281.8M
$18.6M
Q4 24
$294.2M
$20.2M
Q3 24
$305.7M
$19.3M
Q2 24
$306.7M
$10.6M
Total Debt
AMRN
AMRN
CLDT
CLDT
Q1 26
Q4 25
$338.9M
Q3 25
$338.8M
Q2 25
$351.2M
Q1 25
$381.1M
Q4 24
$406.9M
Q3 24
Q2 24
Stockholders' Equity
AMRN
AMRN
CLDT
CLDT
Q1 26
Q4 25
$459.3M
$740.8M
Q3 25
$458.9M
$749.4M
Q2 25
$464.9M
$754.1M
Q1 25
$473.7M
$754.7M
Q4 24
$486.2M
$758.2M
Q3 24
$531.4M
$765.3M
Q2 24
$551.9M
$766.5M
Total Assets
AMRN
AMRN
CLDT
CLDT
Q1 26
$645.8M
Q4 25
$670.8M
$1.2B
Q3 25
$659.8M
$1.2B
Q2 25
$670.1M
$1.2B
Q1 25
$655.7M
$1.2B
Q4 24
$685.3M
$1.3B
Q3 24
$750.6M
$1.3B
Q2 24
$799.9M
$1.3B
Debt / Equity
AMRN
AMRN
CLDT
CLDT
Q1 26
Q4 25
0.46×
Q3 25
0.45×
Q2 25
0.47×
Q1 25
0.50×
Q4 24
0.54×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRN
AMRN
CLDT
CLDT
Operating Cash FlowLast quarter
$64.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
13.90×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRN
AMRN
CLDT
CLDT
Q1 26
Q4 25
$15.3M
$64.1M
Q3 25
$-12.7M
$25.6M
Q2 25
$16.6M
$22.1M
Q1 25
$-12.5M
$4.2M
Q4 24
$-13.3M
$73.8M
Q3 24
$-2.4M
$28.8M
Q2 24
$-2.7M
$25.2M
Cash Conversion
AMRN
AMRN
CLDT
CLDT
Q1 26
Q4 25
13.90×
Q3 25
7.24×
Q2 25
4.10×
Q1 25
2.73×
Q4 24
Q3 24
6.78×
Q2 24
-1.81×
3.68×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRN
AMRN

U.S$35.6M79%
Europe$4.9M11%
Rest-of-World (ROW)$2.8M6%
Licensing & Royalties$1.8M4%

CLDT
CLDT

Occupancy$61.5M91%
Hotel Other$4.2M6%
Food And Beverage$1.8M3%
Hotel$1.1M2%

Related Comparisons